Biofrontera Inc. (NASDAQ:BFRI) Short Interest Update

Biofrontera Inc. (NASDAQ:BFRI) was the recipient of a significant increase in short interest during the month of December. As of December 15th, there was short interest totaling 50,833 shares, an increase of 56.2% from the November 30th total of 32,540 shares. Based on an average daily trading volume, of 119,315 shares, the short-interest ratio is presently 0.4 days. Currently, 0.5% of the company’s shares are sold short. Currently, 0.5% of the company’s shares are sold short. Based on an average daily trading volume, of 119,315 shares, the short-interest ratio is presently 0.4 days.

Analyst Upgrades and Downgrades

BFRI has been the topic of several recent analyst reports. Weiss Ratings reissued a “sell (e+)” rating on shares of Biofrontera in a research note on Thursday, October 30th. Benchmark reiterated a “buy” rating on shares of Biofrontera in a report on Friday, November 14th. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $2.75.

Biofrontera Trading Up 0.2%

Shares of NASDAQ:BFRI opened at $0.72 on Monday. The firm has a market cap of $8.40 million, a price-to-earnings ratio of -0.44 and a beta of 0.57. Biofrontera has a 12 month low of $0.54 and a 12 month high of $1.87. The company’s fifty day simple moving average is $0.89 and its 200 day simple moving average is $0.88. The company has a quick ratio of 0.80, a current ratio of 1.15 and a debt-to-equity ratio of 8.99.

Biofrontera (NASDAQ:BFRI) last announced its earnings results on Wednesday, November 12th. The company reported ($0.59) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.60) by $0.01. Biofrontera had a negative net margin of 47.28% and a negative return on equity of 1,104.09%. The firm had revenue of $6.99 million during the quarter, compared to analyst estimates of $7.00 million. As a group, research analysts forecast that Biofrontera will post -3.01 EPS for the current fiscal year.

Hedge Funds Weigh In On Biofrontera

A hedge fund recently raised its stake in Biofrontera stock. Rosalind Advisors Inc. increased its stake in shares of Biofrontera Inc. (NASDAQ:BFRI) by 51.5% during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 976,448 shares of the company’s stock after acquiring an additional 332,055 shares during the period. Biofrontera comprises approximately 0.3% of Rosalind Advisors Inc.’s investment portfolio, making the stock its 27th largest holding. Rosalind Advisors Inc. owned 9.63% of Biofrontera worth $695,000 as of its most recent SEC filing. Institutional investors own 10.08% of the company’s stock.

About Biofrontera

Biofrontera AG is a specialty biopharmaceutical company focused on the research, development and commercialization of products for dermatological applications. The company’s core expertise lies in photodynamic therapy (PDT), a treatment modality that uses a photosensitizing agent activated by a specific light source to target diseased skin cells while sparing surrounding healthy tissue.

The flagship product in Biofrontera’s portfolio is Ameluz (aminolevulinic acid hydrochloride 10 % gel), which has received marketing approval in the European Union for treatment of actinic keratosis and basal cell carcinoma, and in the United States for actinic keratosis.